公开(公告)号：WO2023060193A1

公开(公告)日：2023-04-13

申请号：PCT/US2022/077695

申请日：2022-10-06

Applicant: DEKA PRODUCTS LIMITED PARTNERSHIP

Inventor： JOHNSON, Hans E. ,  REMEC, Andrew G. ,  CANNAN, David D.B. ,  VIOLETTE, Keith D. ,  NORRIS, Matthew A. ,  MOREAU, Timothy D. ,  BIBEAU, Travis G. ,  BRADLEY, Margaret B. ,  JACOBSON, Stuart A. ,  GLOEB-MCDONALD, Robert G. ,  BOWDEN, Scott R. ,  ANDREWS, Richard E. ,  LOPRIORE, Dominic P. ,  NAEEM, Alden S. ,  NARO, Trevor M. ,  SIMM, David A.

IPC: A61M5/315 ,  A61M5/48 ,  F16H25/20 ,  A61M2005/31588 ,  A61M2202/09 ,  A61M2205/3331 ,  A61M2205/502 ,  A61M5/001 ,  A61M5/2033 ,  A61M5/3129 ,  A61M5/31501 ,  A61M5/31511 ,  A61M5/31578 ,  A61M5/31585 ,  A61M5/486

Abstract: A system and method to enable treatment through cell therapy. The system can enable cell injection such as, for example, injecting beta cells/islets, cartilage cells, fat cells, and others. The system and method ensure that the delivery rate and delivered volume of the material pumped through a tube and into the injection needle is consistent over the course of the start-operation-stop process from run to run. The system and method can automatically stop delivery and alarm if an occlusion is detected during delivery.